Abbreviated MRI and Contrast Mammography Outperform Ultrasound in Detecting Breast Cancer in Dense Breasts: Study
UK: UK researchers have found in a randomized trial that supplementary imaging techniques, such as abbreviated MRI and contrast-enhanced mammography, detected more breast cancers than automated whole-breast ultrasound (ABUS) in women with dense breasts and normal mammograms. These techniques also identified invasive tumors at half the size compared to those found using ultrasound. However, their improved detection came with the drawback of higher recall rates.
The findings stem from the interim analysis of the Breast Screening – Risk Adaptive Imaging for Density (BRAID) randomized controlled trial, published in The Lancet, led by Prof Fiona J Gilbert from the Department of Radiology, University of Cambridge.
The trial, conducted across ten breast screening sites in the UK, aimed to evaluate the most effective supplemental imaging method for women aged 50–70 who had dense breasts and no abnormalities on routine mammography. Participants were randomly assigned to receive abbreviated MRI, ABUS, contrast-enhanced mammography, or continue with standard digital mammography, depending on the availability of each technique at the site.
Between October 2019 and March 2024, 9,361 women were recruited. Of these, 6,305 underwent additional imaging — 2,130 received abbreviated MRI, 2,141 underwent ABUS, and 2,035 had contrast-enhanced mammography. The primary goal was to assess the cancer detection rate confirmed through biopsy.
The key findings were as follows:
- Abbreviated MRI detected 17.4 breast cancers per 1,000 examinations.
- Contrast-enhanced mammography identified 19.2 cancers per 1,000 examinations.
- Automated whole-breast ultrasound (ABUS) detected 4.2 cancers per 1,000 examinations.
- Invasive cancers comprised 15.0 per 1,000 for abbreviated MRI, 15.7 per 1,000 for contrast-enhanced mammography, and 4.2 per 1,000 for ABUS.
- Invasive tumors detected using contrast-based methods were significantly smaller than those identified by ABUS.
- Contrast-based imaging techniques had higher recall rates, resulting in more follow-up procedures and potential patient anxiety.
- Adverse events were uncommon but occurred mainly in the contrast-enhanced mammography group, with 24 contrast-related reactions and three cases of extravasation reported.
According to the authors, the BRAID trial is the first of its kind to directly compare these three supplemental imaging modalities in a randomized setting. The evidence suggests that abbreviated MRI and contrast-enhanced mammography may enhance early detection efforts in women with dense breasts, a group for whom conventional mammography often falls short.
While the findings show promise for incorporating these techniques into breast cancer screening programs, the authors emphasize that further research is needed to determine the long-term benefits and possible harms, including overdiagnosis.
"Abbreviated MRI and contrast-enhanced mammography found three times more invasive cancers than ABUS, and the tumors were about half the size," the authors wrote, adding, "These results suggest that extra imaging can help catch cancer earlier in women with dense breasts, though the risk of overdiagnosis is still unclear."
Reference:
Gilbert, F. J., et al. (2025). Comparison of supplemental breast cancer imaging techniques—interim results from the BRAID randomised controlled trial. The Lancet. doi.org/10.1016/S0140-6736(25)00582-3.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.